Insiders · AKYA

Pascal Bamford

Chief Clinical Officer at Akoya Biosciences, Inc. (AKYA) since August 2024

Pascal Bamford has filed 6 insider reports with the SEC since September 2024, as chief Clinical Officer at Akoya Biosciences, Inc. (AKYA). The latest filing, on July 11, 2025, reports other acquisition or disposition at Akoya Biosciences, Inc. (AKYA).

Filings
6
Companies
1
Bought on market
None
Sold on market
None

Companies where Pascal Bamford is an insider

CompanyRoleShares heldBoughtSoldAvg buyPrice nowLast filing
Akoya Biosciences, Inc. logo
AKYA
Akoya Biosciences, Inc.
Chief Clinical Officersince August 20240Jul 11, 2025

Shares held: common shares owned directly after the latest filing that states it. Avg buy: open-market purchase dollars divided by shares bought, every filing on record.

Every filing

Compare Pascal Bamford with

Other insiders at the same companies

Questions about Pascal Bamford

What is Pascal Bamford's role at Akoya Biosciences, Inc.?
Pascal Bamford reports to the SEC as chief Clinical Officer at Akoya Biosciences, Inc. (AKYA), according to the latest filing on July 11, 2025.
Has Pascal Bamford bought or sold stock recently?
No open-market purchases or sales by Pascal Bamford are on file. The filings report other acquisition or disposition, shares withheld for taxes or exercise price and grant or award.
How do I get alerts when Pascal Bamford files?
Follow Pascal Bamford on Quantisnow and you get an email, and a phone notification on Plus, within minutes of each new Form 4 or Form 5, and of each Form 144 notice of a planned sale.

From SEC Forms 3, 4, 5 and 144 filed by Pascal Bamford (SEC CIK 0002035474). Totals count each trade once, skipping amendments whose original is on file, from Sep 4, 2024 on. View on SEC EDGAR · Get this as JSON